nodes	percent_of_prediction	percent_of_DWPC	metapath
Temozolomide—Alkylating Activity—Mechlorethamine—lymphatic system cancer	0.508	0.591	CiPCiCtD
Temozolomide—Alkylating Activity—Carmustine—lymphatic system cancer	0.352	0.409	CiPCiCtD
Temozolomide—CYP3A4—Cytarabine—lymphatic system cancer	0.0183	0.318	CbGbCtD
Temozolomide—CYP3A4—Teniposide—lymphatic system cancer	0.0181	0.313	CbGbCtD
Temozolomide—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0126	0.219	CbGbCtD
Temozolomide—CYP3A4—Vincristine—lymphatic system cancer	0.00869	0.151	CbGbCtD
Temozolomide—Cough—Bleomycin—lymphatic system cancer	9.05e-05	0.00111	CcSEcCtD
Temozolomide—Angiopathy—Vincristine—lymphatic system cancer	9.01e-05	0.0011	CcSEcCtD
Temozolomide—Aplastic anaemia—Methotrexate—lymphatic system cancer	9e-05	0.0011	CcSEcCtD
Temozolomide—Diarrhoea—Teniposide—lymphatic system cancer	8.99e-05	0.0011	CcSEcCtD
Temozolomide—Mediastinal disorder—Vincristine—lymphatic system cancer	8.95e-05	0.00109	CcSEcCtD
Temozolomide—Myalgia—Bleomycin—lymphatic system cancer	8.83e-05	0.00108	CcSEcCtD
Temozolomide—Alopecia—Vincristine—lymphatic system cancer	8.77e-05	0.00107	CcSEcCtD
Temozolomide—Back pain—Carmustine—lymphatic system cancer	8.76e-05	0.00107	CcSEcCtD
Temozolomide—Discomfort—Bleomycin—lymphatic system cancer	8.72e-05	0.00107	CcSEcCtD
Temozolomide—Mental disorder—Vincristine—lymphatic system cancer	8.7e-05	0.00106	CcSEcCtD
Temozolomide—Chills—Mitoxantrone—lymphatic system cancer	8.67e-05	0.00106	CcSEcCtD
Temozolomide—Neoplasm—Methotrexate—lymphatic system cancer	8.67e-05	0.00106	CcSEcCtD
Temozolomide—Alopecia—Mitoxantrone—lymphatic system cancer	8.54e-05	0.00104	CcSEcCtD
Temozolomide—Confusional state—Bleomycin—lymphatic system cancer	8.53e-05	0.00104	CcSEcCtD
Temozolomide—Vision blurred—Carmustine—lymphatic system cancer	8.53e-05	0.00104	CcSEcCtD
Temozolomide—Hypersensitivity—Fludarabine—lymphatic system cancer	8.5e-05	0.00104	CcSEcCtD
Temozolomide—Tremor—Carmustine—lymphatic system cancer	8.48e-05	0.00104	CcSEcCtD
Temozolomide—Anaphylactic shock—Bleomycin—lymphatic system cancer	8.46e-05	0.00103	CcSEcCtD
Temozolomide—Oedema—Bleomycin—lymphatic system cancer	8.46e-05	0.00103	CcSEcCtD
Temozolomide—Erythema—Mitoxantrone—lymphatic system cancer	8.41e-05	0.00103	CcSEcCtD
Temozolomide—Infection—Bleomycin—lymphatic system cancer	8.41e-05	0.00103	CcSEcCtD
Temozolomide—Anaemia—Carmustine—lymphatic system cancer	8.37e-05	0.00102	CcSEcCtD
Temozolomide—Back pain—Vincristine—lymphatic system cancer	8.36e-05	0.00102	CcSEcCtD
Temozolomide—Vomiting—Teniposide—lymphatic system cancer	8.35e-05	0.00102	CcSEcCtD
Temozolomide—Agitation—Carmustine—lymphatic system cancer	8.32e-05	0.00102	CcSEcCtD
Temozolomide—Thrombocytopenia—Bleomycin—lymphatic system cancer	8.29e-05	0.00101	CcSEcCtD
Temozolomide—Asthenia—Fludarabine—lymphatic system cancer	8.28e-05	0.00101	CcSEcCtD
Temozolomide—Rash—Teniposide—lymphatic system cancer	8.28e-05	0.00101	CcSEcCtD
Temozolomide—Dermatitis—Teniposide—lymphatic system cancer	8.27e-05	0.00101	CcSEcCtD
Temozolomide—Dysgeusia—Mitoxantrone—lymphatic system cancer	8.24e-05	0.00101	CcSEcCtD
Temozolomide—Headache—Teniposide—lymphatic system cancer	8.23e-05	0.00101	CcSEcCtD
Temozolomide—Pruritus—Fludarabine—lymphatic system cancer	8.17e-05	0.000998	CcSEcCtD
Temozolomide—Back pain—Mitoxantrone—lymphatic system cancer	8.14e-05	0.000994	CcSEcCtD
Temozolomide—Leukopenia—Carmustine—lymphatic system cancer	8.1e-05	0.00099	CcSEcCtD
Temozolomide—Anorexia—Bleomycin—lymphatic system cancer	8.07e-05	0.000985	CcSEcCtD
Temozolomide—Thrombophlebitis—Methotrexate—lymphatic system cancer	8.04e-05	0.000982	CcSEcCtD
Temozolomide—Anaemia—Vincristine—lymphatic system cancer	7.99e-05	0.000976	CcSEcCtD
Temozolomide—Agitation—Vincristine—lymphatic system cancer	7.94e-05	0.00097	CcSEcCtD
Temozolomide—Vision blurred—Mitoxantrone—lymphatic system cancer	7.93e-05	0.000969	CcSEcCtD
Temozolomide—Diarrhoea—Fludarabine—lymphatic system cancer	7.9e-05	0.000965	CcSEcCtD
Temozolomide—Convulsion—Carmustine—lymphatic system cancer	7.84e-05	0.000958	CcSEcCtD
Temozolomide—Hypertension—Carmustine—lymphatic system cancer	7.81e-05	0.000955	CcSEcCtD
Temozolomide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	7.81e-05	0.000954	CcSEcCtD
Temozolomide—Nausea—Teniposide—lymphatic system cancer	7.8e-05	0.000953	CcSEcCtD
Temozolomide—Anaemia—Mitoxantrone—lymphatic system cancer	7.78e-05	0.00095	CcSEcCtD
Temozolomide—Vertigo—Vincristine—lymphatic system cancer	7.76e-05	0.000948	CcSEcCtD
Temozolomide—Hepatic failure—Methotrexate—lymphatic system cancer	7.75e-05	0.000946	CcSEcCtD
Temozolomide—Leukopenia—Vincristine—lymphatic system cancer	7.73e-05	0.000945	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	7.71e-05	0.000942	CcSEcCtD
Temozolomide—Myalgia—Carmustine—lymphatic system cancer	7.71e-05	0.000941	CcSEcCtD
Temozolomide—Anxiety—Carmustine—lymphatic system cancer	7.68e-05	0.000938	CcSEcCtD
Temozolomide—Paraesthesia—Bleomycin—lymphatic system cancer	7.6e-05	0.000928	CcSEcCtD
Temozolomide—Malaise—Mitoxantrone—lymphatic system cancer	7.59e-05	0.000927	CcSEcCtD
Temozolomide—Dyspnoea—Bleomycin—lymphatic system cancer	7.54e-05	0.000922	CcSEcCtD
Temozolomide—Leukopenia—Mitoxantrone—lymphatic system cancer	7.53e-05	0.00092	CcSEcCtD
Temozolomide—Convulsion—Vincristine—lymphatic system cancer	7.49e-05	0.000914	CcSEcCtD
Temozolomide—Hypertension—Vincristine—lymphatic system cancer	7.46e-05	0.000911	CcSEcCtD
Temozolomide—Confusional state—Carmustine—lymphatic system cancer	7.45e-05	0.00091	CcSEcCtD
Temozolomide—Oedema—Carmustine—lymphatic system cancer	7.39e-05	0.000902	CcSEcCtD
Temozolomide—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	7.38e-05	0.000901	CcSEcCtD
Temozolomide—Decreased appetite—Bleomycin—lymphatic system cancer	7.36e-05	0.000899	CcSEcCtD
Temozolomide—Myalgia—Vincristine—lymphatic system cancer	7.36e-05	0.000899	CcSEcCtD
Temozolomide—Cough—Mitoxantrone—lymphatic system cancer	7.34e-05	0.000897	CcSEcCtD
Temozolomide—Infection—Carmustine—lymphatic system cancer	7.34e-05	0.000896	CcSEcCtD
Temozolomide—Vomiting—Fludarabine—lymphatic system cancer	7.34e-05	0.000896	CcSEcCtD
Temozolomide—Convulsion—Mitoxantrone—lymphatic system cancer	7.29e-05	0.000891	CcSEcCtD
Temozolomide—Rash—Fludarabine—lymphatic system cancer	7.28e-05	0.000889	CcSEcCtD
Temozolomide—Dermatitis—Fludarabine—lymphatic system cancer	7.27e-05	0.000888	CcSEcCtD
Temozolomide—Hypertension—Mitoxantrone—lymphatic system cancer	7.26e-05	0.000887	CcSEcCtD
Temozolomide—Pain—Bleomycin—lymphatic system cancer	7.24e-05	0.000884	CcSEcCtD
Temozolomide—Thrombocytopenia—Carmustine—lymphatic system cancer	7.23e-05	0.000884	CcSEcCtD
Temozolomide—Headache—Fludarabine—lymphatic system cancer	7.23e-05	0.000883	CcSEcCtD
Temozolomide—Myalgia—Mitoxantrone—lymphatic system cancer	7.16e-05	0.000875	CcSEcCtD
Temozolomide—Arthralgia—Mitoxantrone—lymphatic system cancer	7.16e-05	0.000875	CcSEcCtD
Temozolomide—Anxiety—Mitoxantrone—lymphatic system cancer	7.14e-05	0.000872	CcSEcCtD
Temozolomide—Discomfort—Mitoxantrone—lymphatic system cancer	7.08e-05	0.000865	CcSEcCtD
Temozolomide—Oedema—Vincristine—lymphatic system cancer	7.05e-05	0.000861	CcSEcCtD
Temozolomide—Anaphylactic shock—Vincristine—lymphatic system cancer	7.05e-05	0.000861	CcSEcCtD
Temozolomide—Anorexia—Carmustine—lymphatic system cancer	7.04e-05	0.00086	CcSEcCtD
Temozolomide—Infection—Vincristine—lymphatic system cancer	7.01e-05	0.000856	CcSEcCtD
Temozolomide—Feeling abnormal—Bleomycin—lymphatic system cancer	6.97e-05	0.000852	CcSEcCtD
Temozolomide—Confusional state—Mitoxantrone—lymphatic system cancer	6.92e-05	0.000846	CcSEcCtD
Temozolomide—Nervous system disorder—Vincristine—lymphatic system cancer	6.92e-05	0.000845	CcSEcCtD
Temozolomide—Thrombocytopenia—Vincristine—lymphatic system cancer	6.9e-05	0.000843	CcSEcCtD
Temozolomide—Oedema—Mitoxantrone—lymphatic system cancer	6.87e-05	0.000839	CcSEcCtD
Temozolomide—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	6.87e-05	0.000839	CcSEcCtD
Temozolomide—Nausea—Fludarabine—lymphatic system cancer	6.86e-05	0.000838	CcSEcCtD
Temozolomide—Infection—Mitoxantrone—lymphatic system cancer	6.82e-05	0.000833	CcSEcCtD
Temozolomide—Hyperhidrosis—Vincristine—lymphatic system cancer	6.82e-05	0.000833	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	6.73e-05	0.000822	CcSEcCtD
Temozolomide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	6.72e-05	0.000821	CcSEcCtD
Temozolomide—Urticaria—Bleomycin—lymphatic system cancer	6.72e-05	0.000821	CcSEcCtD
Temozolomide—Anorexia—Vincristine—lymphatic system cancer	6.72e-05	0.000821	CcSEcCtD
Temozolomide—Body temperature increased—Bleomycin—lymphatic system cancer	6.69e-05	0.000817	CcSEcCtD
Temozolomide—Insomnia—Carmustine—lymphatic system cancer	6.68e-05	0.000816	CcSEcCtD
Temozolomide—Skin disorder—Mitoxantrone—lymphatic system cancer	6.67e-05	0.000815	CcSEcCtD
Temozolomide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	6.64e-05	0.000811	CcSEcCtD
Temozolomide—Paraesthesia—Carmustine—lymphatic system cancer	6.63e-05	0.00081	CcSEcCtD
Temozolomide—Mood swings—Methotrexate—lymphatic system cancer	6.59e-05	0.000806	CcSEcCtD
Temozolomide—Dyspnoea—Carmustine—lymphatic system cancer	6.59e-05	0.000805	CcSEcCtD
Temozolomide—Somnolence—Carmustine—lymphatic system cancer	6.57e-05	0.000802	CcSEcCtD
Temozolomide—Anorexia—Mitoxantrone—lymphatic system cancer	6.55e-05	0.0008	CcSEcCtD
Temozolomide—Ataxia—Methotrexate—lymphatic system cancer	6.55e-05	0.0008	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	6.42e-05	0.000785	CcSEcCtD
Temozolomide—Decreased appetite—Carmustine—lymphatic system cancer	6.42e-05	0.000784	CcSEcCtD
Temozolomide—Insomnia—Vincristine—lymphatic system cancer	6.38e-05	0.000779	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	6.38e-05	0.000779	CcSEcCtD
Temozolomide—Paraesthesia—Vincristine—lymphatic system cancer	6.33e-05	0.000774	CcSEcCtD
Temozolomide—Pain—Carmustine—lymphatic system cancer	6.32e-05	0.000772	CcSEcCtD
Temozolomide—Constipation—Carmustine—lymphatic system cancer	6.32e-05	0.000772	CcSEcCtD
Temozolomide—Breast disorder—Methotrexate—lymphatic system cancer	6.29e-05	0.000768	CcSEcCtD
Temozolomide—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	6.27e-05	0.000766	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	6.26e-05	0.000764	CcSEcCtD
Temozolomide—Hypersensitivity—Bleomycin—lymphatic system cancer	6.23e-05	0.000762	CcSEcCtD
Temozolomide—Paraesthesia—Mitoxantrone—lymphatic system cancer	6.17e-05	0.000753	CcSEcCtD
Temozolomide—Decreased appetite—Vincristine—lymphatic system cancer	6.13e-05	0.000749	CcSEcCtD
Temozolomide—Dyspnoea—Mitoxantrone—lymphatic system cancer	6.12e-05	0.000748	CcSEcCtD
Temozolomide—Somnolence—Mitoxantrone—lymphatic system cancer	6.11e-05	0.000746	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	6.09e-05	0.000744	CcSEcCtD
Temozolomide—Feeling abnormal—Carmustine—lymphatic system cancer	6.09e-05	0.000744	CcSEcCtD
Temozolomide—Fatigue—Vincristine—lymphatic system cancer	6.08e-05	0.000743	CcSEcCtD
Temozolomide—Asthenia—Bleomycin—lymphatic system cancer	6.07e-05	0.000742	CcSEcCtD
Temozolomide—Dyspepsia—Mitoxantrone—lymphatic system cancer	6.05e-05	0.000738	CcSEcCtD
Temozolomide—Gastrointestinal pain—Carmustine—lymphatic system cancer	6.04e-05	0.000738	CcSEcCtD
Temozolomide—Constipation—Vincristine—lymphatic system cancer	6.03e-05	0.000737	CcSEcCtD
Temozolomide—Pain—Vincristine—lymphatic system cancer	6.03e-05	0.000737	CcSEcCtD
Temozolomide—Pruritus—Bleomycin—lymphatic system cancer	5.99e-05	0.000731	CcSEcCtD
Temozolomide—Decreased appetite—Mitoxantrone—lymphatic system cancer	5.97e-05	0.000729	CcSEcCtD
Temozolomide—Fatigue—Mitoxantrone—lymphatic system cancer	5.92e-05	0.000723	CcSEcCtD
Temozolomide—Pain—Mitoxantrone—lymphatic system cancer	5.87e-05	0.000717	CcSEcCtD
Temozolomide—Constipation—Mitoxantrone—lymphatic system cancer	5.87e-05	0.000717	CcSEcCtD
Temozolomide—Abdominal pain—Carmustine—lymphatic system cancer	5.84e-05	0.000713	CcSEcCtD
Temozolomide—Body temperature increased—Carmustine—lymphatic system cancer	5.84e-05	0.000713	CcSEcCtD
Temozolomide—Gastrointestinal pain—Vincristine—lymphatic system cancer	5.77e-05	0.000704	CcSEcCtD
Temozolomide—Pancytopenia—Methotrexate—lymphatic system cancer	5.71e-05	0.000698	CcSEcCtD
Temozolomide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	5.66e-05	0.000691	CcSEcCtD
Temozolomide—Neutropenia—Methotrexate—lymphatic system cancer	5.63e-05	0.000687	CcSEcCtD
Temozolomide—Dysuria—Methotrexate—lymphatic system cancer	5.63e-05	0.000687	CcSEcCtD
Temozolomide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	5.62e-05	0.000686	CcSEcCtD
Temozolomide—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	5.59e-05	0.000683	CcSEcCtD
Temozolomide—Abdominal pain—Vincristine—lymphatic system cancer	5.57e-05	0.000681	CcSEcCtD
Temozolomide—Body temperature increased—Vincristine—lymphatic system cancer	5.57e-05	0.000681	CcSEcCtD
Temozolomide—Erectile dysfunction—Methotrexate—lymphatic system cancer	5.54e-05	0.000677	CcSEcCtD
Temozolomide—Photosensitivity reaction—Methotrexate—lymphatic system cancer	5.49e-05	0.000671	CcSEcCtD
Temozolomide—Urticaria—Mitoxantrone—lymphatic system cancer	5.46e-05	0.000666	CcSEcCtD
Temozolomide—Hypersensitivity—Carmustine—lymphatic system cancer	5.44e-05	0.000665	CcSEcCtD
Temozolomide—Abdominal pain—Mitoxantrone—lymphatic system cancer	5.43e-05	0.000663	CcSEcCtD
Temozolomide—Body temperature increased—Mitoxantrone—lymphatic system cancer	5.43e-05	0.000663	CcSEcCtD
Temozolomide—Pneumonia—Methotrexate—lymphatic system cancer	5.4e-05	0.000659	CcSEcCtD
Temozolomide—Vomiting—Bleomycin—lymphatic system cancer	5.38e-05	0.000657	CcSEcCtD
Temozolomide—Infestation—Methotrexate—lymphatic system cancer	5.36e-05	0.000655	CcSEcCtD
Temozolomide—Infestation NOS—Methotrexate—lymphatic system cancer	5.36e-05	0.000655	CcSEcCtD
Temozolomide—Depression—Methotrexate—lymphatic system cancer	5.35e-05	0.000653	CcSEcCtD
Temozolomide—Rash—Bleomycin—lymphatic system cancer	5.34e-05	0.000652	CcSEcCtD
Temozolomide—Dermatitis—Bleomycin—lymphatic system cancer	5.33e-05	0.000651	CcSEcCtD
Temozolomide—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	5.32e-05	0.00065	CcSEcCtD
Temozolomide—Asthenia—Carmustine—lymphatic system cancer	5.3e-05	0.000647	CcSEcCtD
Temozolomide—Stomatitis—Methotrexate—lymphatic system cancer	5.23e-05	0.000639	CcSEcCtD
Temozolomide—Hypersensitivity—Vincristine—lymphatic system cancer	5.2e-05	0.000635	CcSEcCtD
Temozolomide—Hepatobiliary disease—Methotrexate—lymphatic system cancer	5.07e-05	0.00062	CcSEcCtD
Temozolomide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	5.06e-05	0.000618	CcSEcCtD
Temozolomide—Asthenia—Vincristine—lymphatic system cancer	5.06e-05	0.000618	CcSEcCtD
Temozolomide—Diarrhoea—Carmustine—lymphatic system cancer	5.05e-05	0.000617	CcSEcCtD
Temozolomide—Nausea—Bleomycin—lymphatic system cancer	5.03e-05	0.000614	CcSEcCtD
Temozolomide—Asthenia—Mitoxantrone—lymphatic system cancer	4.93e-05	0.000602	CcSEcCtD
Temozolomide—Dizziness—Carmustine—lymphatic system cancer	4.88e-05	0.000597	CcSEcCtD
Temozolomide—Haemoglobin—Methotrexate—lymphatic system cancer	4.84e-05	0.000591	CcSEcCtD
Temozolomide—Diarrhoea—Vincristine—lymphatic system cancer	4.82e-05	0.000589	CcSEcCtD
Temozolomide—Haemorrhage—Methotrexate—lymphatic system cancer	4.82e-05	0.000588	CcSEcCtD
Temozolomide—Hepatitis—Methotrexate—lymphatic system cancer	4.82e-05	0.000588	CcSEcCtD
Temozolomide—Pharyngitis—Methotrexate—lymphatic system cancer	4.78e-05	0.000584	CcSEcCtD
Temozolomide—Urinary tract disorder—Methotrexate—lymphatic system cancer	4.76e-05	0.000581	CcSEcCtD
Temozolomide—Urethral disorder—Methotrexate—lymphatic system cancer	4.72e-05	0.000577	CcSEcCtD
Temozolomide—Diarrhoea—Mitoxantrone—lymphatic system cancer	4.7e-05	0.000574	CcSEcCtD
Temozolomide—Vomiting—Carmustine—lymphatic system cancer	4.7e-05	0.000574	CcSEcCtD
Temozolomide—Dizziness—Vincristine—lymphatic system cancer	4.66e-05	0.00057	CcSEcCtD
Temozolomide—Rash—Carmustine—lymphatic system cancer	4.66e-05	0.000569	CcSEcCtD
Temozolomide—Dermatitis—Carmustine—lymphatic system cancer	4.65e-05	0.000568	CcSEcCtD
Temozolomide—Visual impairment—Methotrexate—lymphatic system cancer	4.64e-05	0.000567	CcSEcCtD
Temozolomide—Headache—Carmustine—lymphatic system cancer	4.63e-05	0.000565	CcSEcCtD
Temozolomide—Erythema multiforme—Methotrexate—lymphatic system cancer	4.55e-05	0.000556	CcSEcCtD
Temozolomide—Eye disorder—Methotrexate—lymphatic system cancer	4.5e-05	0.00055	CcSEcCtD
Temozolomide—Tinnitus—Methotrexate—lymphatic system cancer	4.49e-05	0.000549	CcSEcCtD
Temozolomide—Vomiting—Vincristine—lymphatic system cancer	4.48e-05	0.000548	CcSEcCtD
Temozolomide—Cardiac disorder—Methotrexate—lymphatic system cancer	4.47e-05	0.000546	CcSEcCtD
Temozolomide—Rash—Vincristine—lymphatic system cancer	4.45e-05	0.000543	CcSEcCtD
Temozolomide—Dermatitis—Vincristine—lymphatic system cancer	4.44e-05	0.000543	CcSEcCtD
Temozolomide—Headache—Vincristine—lymphatic system cancer	4.42e-05	0.00054	CcSEcCtD
Temozolomide—Nausea—Carmustine—lymphatic system cancer	4.39e-05	0.000536	CcSEcCtD
Temozolomide—Angiopathy—Methotrexate—lymphatic system cancer	4.37e-05	0.000534	CcSEcCtD
Temozolomide—Vomiting—Mitoxantrone—lymphatic system cancer	4.37e-05	0.000533	CcSEcCtD
Temozolomide—Immune system disorder—Methotrexate—lymphatic system cancer	4.35e-05	0.000531	CcSEcCtD
Temozolomide—Mediastinal disorder—Methotrexate—lymphatic system cancer	4.34e-05	0.00053	CcSEcCtD
Temozolomide—Rash—Mitoxantrone—lymphatic system cancer	4.33e-05	0.000529	CcSEcCtD
Temozolomide—Dermatitis—Mitoxantrone—lymphatic system cancer	4.33e-05	0.000528	CcSEcCtD
Temozolomide—Chills—Methotrexate—lymphatic system cancer	4.32e-05	0.000528	CcSEcCtD
Temozolomide—Headache—Mitoxantrone—lymphatic system cancer	4.3e-05	0.000526	CcSEcCtD
Temozolomide—Alopecia—Methotrexate—lymphatic system cancer	4.26e-05	0.00052	CcSEcCtD
Temozolomide—Mental disorder—Methotrexate—lymphatic system cancer	4.22e-05	0.000515	CcSEcCtD
Temozolomide—Erythema—Methotrexate—lymphatic system cancer	4.19e-05	0.000512	CcSEcCtD
Temozolomide—Malnutrition—Methotrexate—lymphatic system cancer	4.19e-05	0.000512	CcSEcCtD
Temozolomide—Nausea—Vincristine—lymphatic system cancer	4.19e-05	0.000512	CcSEcCtD
Temozolomide—Dysgeusia—Methotrexate—lymphatic system cancer	4.11e-05	0.000502	CcSEcCtD
Temozolomide—Nausea—Mitoxantrone—lymphatic system cancer	4.08e-05	0.000498	CcSEcCtD
Temozolomide—Back pain—Methotrexate—lymphatic system cancer	4.06e-05	0.000495	CcSEcCtD
Temozolomide—Vision blurred—Methotrexate—lymphatic system cancer	3.95e-05	0.000483	CcSEcCtD
Temozolomide—Ill-defined disorder—Methotrexate—lymphatic system cancer	3.89e-05	0.000475	CcSEcCtD
Temozolomide—Anaemia—Methotrexate—lymphatic system cancer	3.87e-05	0.000473	CcSEcCtD
Temozolomide—Malaise—Methotrexate—lymphatic system cancer	3.78e-05	0.000462	CcSEcCtD
Temozolomide—Vertigo—Methotrexate—lymphatic system cancer	3.77e-05	0.00046	CcSEcCtD
Temozolomide—Leukopenia—Methotrexate—lymphatic system cancer	3.75e-05	0.000458	CcSEcCtD
Temozolomide—Cough—Methotrexate—lymphatic system cancer	3.66e-05	0.000447	CcSEcCtD
Temozolomide—Convulsion—Methotrexate—lymphatic system cancer	3.63e-05	0.000444	CcSEcCtD
Temozolomide—Arthralgia—Methotrexate—lymphatic system cancer	3.57e-05	0.000436	CcSEcCtD
Temozolomide—Myalgia—Methotrexate—lymphatic system cancer	3.57e-05	0.000436	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	3.54e-05	0.000433	CcSEcCtD
Temozolomide—Discomfort—Methotrexate—lymphatic system cancer	3.53e-05	0.000431	CcSEcCtD
Temozolomide—Confusional state—Methotrexate—lymphatic system cancer	3.45e-05	0.000421	CcSEcCtD
Temozolomide—Anaphylactic shock—Methotrexate—lymphatic system cancer	3.42e-05	0.000418	CcSEcCtD
Temozolomide—Infection—Methotrexate—lymphatic system cancer	3.4e-05	0.000415	CcSEcCtD
Temozolomide—Nervous system disorder—Methotrexate—lymphatic system cancer	3.36e-05	0.00041	CcSEcCtD
Temozolomide—Thrombocytopenia—Methotrexate—lymphatic system cancer	3.35e-05	0.000409	CcSEcCtD
Temozolomide—Skin disorder—Methotrexate—lymphatic system cancer	3.32e-05	0.000406	CcSEcCtD
Temozolomide—Hyperhidrosis—Methotrexate—lymphatic system cancer	3.31e-05	0.000404	CcSEcCtD
Temozolomide—Anorexia—Methotrexate—lymphatic system cancer	3.26e-05	0.000398	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	3.12e-05	0.000381	CcSEcCtD
Temozolomide—Insomnia—Methotrexate—lymphatic system cancer	3.09e-05	0.000378	CcSEcCtD
Temozolomide—Paraesthesia—Methotrexate—lymphatic system cancer	3.07e-05	0.000375	CcSEcCtD
Temozolomide—Dyspnoea—Methotrexate—lymphatic system cancer	3.05e-05	0.000373	CcSEcCtD
Temozolomide—Somnolence—Methotrexate—lymphatic system cancer	3.04e-05	0.000372	CcSEcCtD
Temozolomide—Dyspepsia—Methotrexate—lymphatic system cancer	3.01e-05	0.000368	CcSEcCtD
Temozolomide—Decreased appetite—Methotrexate—lymphatic system cancer	2.97e-05	0.000363	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	2.95e-05	0.000361	CcSEcCtD
Temozolomide—Fatigue—Methotrexate—lymphatic system cancer	2.95e-05	0.00036	CcSEcCtD
Temozolomide—Pain—Methotrexate—lymphatic system cancer	2.93e-05	0.000357	CcSEcCtD
Temozolomide—Feeling abnormal—Methotrexate—lymphatic system cancer	2.82e-05	0.000344	CcSEcCtD
Temozolomide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	2.8e-05	0.000342	CcSEcCtD
Temozolomide—Urticaria—Methotrexate—lymphatic system cancer	2.72e-05	0.000332	CcSEcCtD
Temozolomide—Abdominal pain—Methotrexate—lymphatic system cancer	2.7e-05	0.00033	CcSEcCtD
Temozolomide—Body temperature increased—Methotrexate—lymphatic system cancer	2.7e-05	0.00033	CcSEcCtD
Temozolomide—Hypersensitivity—Methotrexate—lymphatic system cancer	2.52e-05	0.000308	CcSEcCtD
Temozolomide—Asthenia—Methotrexate—lymphatic system cancer	2.45e-05	0.0003	CcSEcCtD
Temozolomide—Pruritus—Methotrexate—lymphatic system cancer	2.42e-05	0.000296	CcSEcCtD
Temozolomide—Diarrhoea—Methotrexate—lymphatic system cancer	2.34e-05	0.000286	CcSEcCtD
Temozolomide—Dizziness—Methotrexate—lymphatic system cancer	2.26e-05	0.000276	CcSEcCtD
Temozolomide—Vomiting—Methotrexate—lymphatic system cancer	2.18e-05	0.000266	CcSEcCtD
Temozolomide—Rash—Methotrexate—lymphatic system cancer	2.16e-05	0.000264	CcSEcCtD
Temozolomide—Dermatitis—Methotrexate—lymphatic system cancer	2.16e-05	0.000263	CcSEcCtD
Temozolomide—Headache—Methotrexate—lymphatic system cancer	2.14e-05	0.000262	CcSEcCtD
Temozolomide—Nausea—Methotrexate—lymphatic system cancer	2.03e-05	0.000248	CcSEcCtD
